Articles

While previous studies have linked vitamin D deficiency with obesity….

Men who are permanently stressed are significantly more likely to develop type 2 diabetes than men with no stress in their lives….

A high intake of supplemental calcium appears to be associated with an increased risk of CVD death in men but….

One more GLP-1 agonist gets approved in Europe…. The European Commission has granted approval of lixisenatide (Lyxumia, Sanofi) for the treatment of adults with type 2 diabetes. The drug, a once-daily glucagon-like peptide 1 (GLP-1) agonist, is indicated to achieve glycemic control in combination with oral glucose-lowering products and/or basal …

With data from the scientific literature, some of the most firmly held beliefs about weight loss are unproven or downright untrue….

Sustained high levels of sugars damage our cells and can….

Today’s baby boomers do not fare very well compared with….

Preliminary evidence from a clinical trial suggests that treatment with GLP-1 receptor agonists was associated with…. Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report …

Also linked to insulin resistance regardless of adiposity or glycemic measurement….

A nutritional supplement may help protect women at risk for gestational diabetes….